BHC

SEC source: 0001127602-18-016654 · form4a.xml · nonDerivative · entry 1

POWER ROBERT N · CIK 0001187303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,109

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant.

F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018.

SEC source: 0001127602-18-016652 · form4a.xml · nonDerivative · entry 1

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,957

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant.

F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018.

SEC source: 0001127602-18-016651 · form4a.xml · nonDerivative · entry 1

KAVANAGH SARAH B · CIK 0001681171 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,745

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant.

F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018.

SEC source: 0001127602-18-016650 · form4a.xml · nonDerivative · entry 1

KARABELAS ARGERIS N · CIK 0001191229 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,013

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant.

F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018.

SEC source: 0001127602-18-016649 · form4a.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,383

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant.

F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018.

SEC source: 0001418812-18-000038 · primary_doc.xml · nonDerivative · entry 1

Hale David Robert · CIK 0001635643 · Director · See Remarks

ValueAct Holdings, L.P. · CIK 0001418814 · Director · See Remarks

ValueAct Capital Master Fund, L.P. · CIK 0001464912 · Director · See Remarks

ValueAct Co-Invest Master Fund, L.P. · CIK 0001579734 · Director · See Remarks

VA Partners I, LLC · CIK 0001418812 · Director · See Remarks

ValueAct Capital Management, L.P. · CIK 0001351069 · Director · See Remarks

ValueAct Capital Management, LLC · CIK 0001351073 · Director · See Remarks

ValueAct Holdings GP, LLC · CIK 0001418813 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,612

F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

F2 · ownership.direct: All board compensation accrues to the benefit of the investors in ValueAct Capital Master Fund, L.P.‎, and not to any individual. Under an agreement with ValueAct Capital, D. Robert Hale is deemed to hold the restricted share units for the benefit of the limited partners of ValueAct Capital Master Fund, L.P. and indirectly for (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.

F3 · ownership.direct: Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001127602-18-016230 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,502

SEC source: 0001127602-18-013772 · form4.xml · nonDerivative · entry 1

WECHSLER AMY B · CIK 0001677300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,007

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-013761 · form4.xml · nonDerivative · entry 1

ROBERTSON RUSSEL C · CIK 0001677301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,213

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-013758 · form4.xml · nonDerivative · entry 1

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,076

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-013755 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,024

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-011394 · form4.xml · nonDerivative · entry 1

Herendeen Paul · CIK 0001374175 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,492

F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction range from $16.09 to $16.10 per Common Share.

F2 · price: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each price within the range reported above.

SEC source: 0001127602-18-011391 · form4.xml · nonDerivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 719,019

SEC source: 0001127602-18-011288 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,062

F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction are within the range of $15.01 to $16.00 per share.

F2 · price: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each price within the range reported above.

SEC source: 0001127602-18-011039 · form4.xml · derivative · entry 3

Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,104

Underlying: Common Stock · 7,104 shares

Expires 2021-03-07

F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 3,552 and the maximum number that can be distributed is 7,104. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 3,552 and the maximum number that can be distributed is 7,104. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

SEC source: 0001127602-18-011039 · form4.xml · derivative · entry 2

Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,697

Underlying: Common Shares, No Par Value · 31,697 shares

Expires 2028-03-07

F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant.

SEC source: 0001127602-18-011039 · form4.xml · nonDerivative · entry 1

Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,259

F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").

SEC source: 0001127602-18-011038 · form4.xml · derivative · entry 3

APPIO THOMAS · CIK 0001683323 · EVP, COMPANY GROUP CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,776

Underlying: Common Stock · 14,776 shares

Expires 2021-03-07

F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 7,388 and the maximum number that can be distributed is 14,776. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 7,388 and the maximum number that can be distributed is 14,776. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

SEC source: 0001127602-18-011038 · form4.xml · derivative · entry 2

APPIO THOMAS · CIK 0001683323 · EVP, COMPANY GROUP CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,923

Underlying: Common Shares, No Par Value · 65,923 shares

Expires 2028-03-07

F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant.

SEC source: 0001127602-18-011038 · form4.xml · nonDerivative · entry 1

APPIO THOMAS · CIK 0001683323 · EVP, COMPANY GROUP CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,086

F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").

SEC source: 0001127602-18-011037 · form4.xml · derivative · entry 3

ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,638

Underlying: Common Stock · 13,638 shares

Expires 2021-03-07

F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 6,819 and the maximum number that can be distributed is 13,638. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 6,819 and the maximum number that can be distributed is 13,638. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

SEC source: 0001127602-18-011037 · form4.xml · derivative · entry 2

ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,853

Underlying: Common Shares, No Par Value · 60,853 shares

Expires 2028-03-07

F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant.

SEC source: 0001127602-18-011037 · form4.xml · nonDerivative · entry 1

ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,181

F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").

SEC source: 0001127602-18-011036 · form4.xml · derivative · entry 3

Herendeen Paul · CIK 0001374175 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,556

Underlying: Common Stock · 79,556 shares

Expires 2021-03-07

F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 39,778 and the maximum number that can be distributed is 79,556. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 39,778 and the maximum number that can be distributed is 79,556. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

SEC source: 0001127602-18-011036 · form4.xml · derivative · entry 2

Herendeen Paul · CIK 0001374175 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,482

Underlying: Common Shares, No Par Value · 177,482 shares

Expires 2028-03-07

F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant.

SEC source: 0001127602-18-011036 · form4.xml · nonDerivative · entry 1

Herendeen Paul · CIK 0001374175 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,492

F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").

SEC source: 0001127602-18-011033 · form4.xml · derivative · entry 3

PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 511,434

Underlying: Common Stock · 511,434 shares

Expires 2021-03-07

F4 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 255,717 and the maximum number that can be distributed is 511,434. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

F4 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 255,717 and the maximum number that can be distributed is 511,434. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.

SEC source: 0001127602-18-011033 · form4.xml · derivative · entry 2

PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,058

Underlying: Common Shares, No Par Value · 338,058 shares

Expires 2028-03-07

F3 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant.

SEC source: 0001127602-18-011033 · form4.xml · nonDerivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 689,019

F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").

F2 · balance_after: Reflects the cancellation, on March 7, 2018, of 933,416 performance-based RSUs granted on May 2, 2016, as reported on a Form 4 filed by the reporting person on May 4, 2016.

SEC source: 0001140361-18-012637 · doc1.xml · nonDerivative · entry 2

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Funds

Disclosed balance after: 20,839,035

F1 · ownership.direct: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.direct: Represent rebalancing transactions between the Funds.

F1 · ownership.nature: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.nature: Represent rebalancing transactions between the Funds.

SEC source: 0001140361-18-012637 · doc1.xml · nonDerivative · entry 1

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Funds

Disclosed balance after: 13,772,406

F1 · ownership.direct: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.direct: Represent rebalancing transactions between the Funds.

F1 · ownership.nature: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.nature: Represent rebalancing transactions between the Funds.

SEC source: 0001127602-18-001435 · form4.xml · nonDerivative · entry 1

APPIO THOMAS · CIK 0001683323 · EVP, COMPANY GROUP CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,631

F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

SEC source: 0001127602-18-001439 · form4.xml · nonDerivative · entry 1

Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,605

F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

SEC source: 0001127602-18-001433 · form4.xml · nonDerivative · entry 1

ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,724

SEC source: 0001127602-18-002719 · form4a.xml · nonDerivative · entry 1

APPIO THOMAS · CIK 0001683323 · EVP, COMPANY GROUP CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,924

F1 · shares: This Form 4/A is being filed to correct the number of shares withheld to satisfy the tax withholding obligations due upon the vesting of Restricted Share Units.

SEC source: 0001127602-18-001241 · form4.xml · nonDerivative · entry 1

Humphries William D. · CIK 0001674278 · EVP, COMPANY GROUP CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,108

SEC source: 0001140361-18-000541 · doc1.xml · nonDerivative · entry 1

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,349

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

F1 · balance_after: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-000372 · form4.xml · nonDerivative · entry 1

ROBERTSON RUSSEL C · CIK 0001677301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,858

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-000343 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,062

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-18-000334 · form4.xml · nonDerivative · entry 1

WECHSLER AMY B · CIK 0001677300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,045

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-17-033073 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,559

SEC source: 0001140361-17-043408 · doc1.xml · nonDerivative · entry 2

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Funds

Disclosed balance after: 20,839,035

F1 · ownership.direct: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.direct: Represent rebalancing transactions between the Funds.

F1 · ownership.nature: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.nature: Represent rebalancing transactions between the Funds.

SEC source: 0001140361-17-043408 · doc1.xml · nonDerivative · entry 1

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Funds

Disclosed balance after: 21,183,251

F1 · ownership.direct: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.direct: Represent rebalancing transactions between the Funds.

F1 · ownership.nature: John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.

F2 · ownership.nature: Represent rebalancing transactions between the Funds.

SEC source: 0001127602-17-029036 · form4.xml · nonDerivative · entry 1

WECHSLER AMY B · CIK 0001677300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,542

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-17-029034 · form4.xml · nonDerivative · entry 1

ROBERTSON RUSSEL C · CIK 0001677301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,054

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-17-029031 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,559

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001140361-17-037671 · doc1.xml · nonDerivative · entry 1

Paulson John · CIK 0001394923 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,026

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

F1 · balance_after: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

SEC source: 0001127602-17-026502 · form4.xml · nonDerivative · entry 1

Herendeen Paul · CIK 0001374175 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,825

F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

SEC source: 0001127602-17-026211 · form4.xml · nonDerivative · entry 2

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,379

SEC source: 0001127602-17-026211 · form4.xml · nonDerivative · entry 1

DE SCHUTTER RICHARD U · CIK 0001083205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,479